Guzman R, Guirao A, Vela E, et al. - Researchers sought to compare the outcomes as well as the cost of lung cancer patients managed medically or surgically in their region, by utilizing real-life data. They also focused on estimating the cost–benefit ratio of a lung cancer screening program (CRIBAR) soon to be deployed in their region (Catalunya, Spain), using this data. Better survival, earlier return to regular home activities, less utilization of healthcare related resources, and a reduced use of tax-payer money were noted in surgically treated lung cancer patients. Overall, findings showed that less expense and better outcomes were associated with surgical treatment of lung cancer, and, for CRIBAR return on investment, it was estimated to break even at 3–6 years. .